Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. (4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone
2. Belsomra
3. Methanone, ((7r)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1h-1,4-diazepin-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)-
4. Mk 4305
5. Mk-4305
6. Mk4305
1. 1030377-33-3
2. Mk-4305
3. Belsomra
4. Mk4305
5. Mk 4305
6. [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone
7. Suvorexant (mk-4305)
8. 5-chloro-2-[(5r)-5-methyl-4-[5-methyl-2-(2h-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole
9. Chembl1083659
10. Chebi:82698
11. 081l192fo9
12. ((7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone
13. Methanone, ((7r)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1h-1,4-diazepin-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)-
14. (r)-(4-(5-chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone.
15. [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
16. Suvorexant [usan:inn]
17. Dora-analogue
18. Unii-081l192fo9
19. Belsomra (tn)
20. Suv
21. Suvorexant [mi]
22. Suvorexant [inn]
23. Suvorexant [jan]
24. Suvorexant (jan/usan)
25. Suvorexant [usan]
26. Suvorexant; Mk 4305
27. Suvorexant [vandf]
28. Suvorexant [who-dd]
29. Amy337
30. Gtpl2890
31. Schembl1586289
32. Suvorexant [orange Book]
33. Dtxsid90145616
34. Ex-a211
35. Belsomra Component Suvorexant
36. Bdbm50318701
37. Mfcd22377755
38. Zinc49036447
39. Akos022185167
40. Cs-0614
41. Db09034
42. Suvorexant Component Of Belsomra
43. (4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone
44. Ac-30276
45. As-74879
46. Hy-10807
47. Bcp0726000197
48. Ft-0697203
49. Sw219649-1
50. D10082
51. J-690010
52. Q7650517
53. Cas:1030377-33-3;mk-4305
54. 5-chloro-2-[(5r)-5-methyl-4-[5-methyl-2-(2h-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole Mk 4305
Molecular Weight | 450.9 g/mol |
---|---|
Molecular Formula | C23H23ClN6O2 |
XLogP3 | 4.9 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 3 |
Exact Mass | 450.1571017 g/mol |
Monoisotopic Mass | 450.1571017 g/mol |
Topological Polar Surface Area | 80.3 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 664 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
FDA Label
Orexin Receptor Antagonists
Substances that bind to and inhibit the action of OREXIN RECEPTORS. Drugs in this class have been used as SLEEP AIDS, PHARMACEUTICAL. (See all compounds classified as Orexin Receptor Antagonists.)
Sleep Aids, Pharmaceutical
Drugs used to induce SLEEP, prevent SLEEPLESSNESS, or treat SLEEP INITIATION AND MAINTENANCE DISORDERS. (See all compounds classified as Sleep Aids, Pharmaceutical.)
N - Nervous system
N05 - Psycholeptics
N05C - Hypnotics and sedatives
N05CM - Other hypnotics and sedatives
N05CM19 - Suvorexant
Absorption
Peak concentrations occur at a median Tmax of 2 hours under fasted conditions. Ingestion of suvorexant with a high-fat meal has no effect on AUC or Cmax, but may delay Tmax by approximately 1.5 hours. Mean absolute bioavailability of 10 mg is 82%.
Route of Elimination
Approximately 66% is eliminated in feces and 23% is eliminated in urine.
Volume of Distribution
Mean volume of distribution is approximately 49 litres.
Suvorexant is primarily metabolized by cytochrome-P450 3A4 enzyme (CYP3A4) with a minor contribution from CYP2C19. Major circulating metabolites are suvorexant and a hydroxy-suvorexant metabolite, which is not expected to be pharmacologically active. There is potential for drug-drug interactions with drugs that inhibit or induce CYP3A4 activity.
Mean half life is approximately 12 hours.
Suvorexant is a dual antagonist of orexin receptors OX1R and OX2R. It exerts its pharmacological effect by inhibiting binding of neuropeptides orexin A and B, also known as hypocretin 1 and 2, that are produced by neurons in the lateral hypothalamus. These neurons control the wake-promoting centers of the brain and are active during wakefulness, especially during motor activities, and stop firing during sleep. By inhibiting the reinforcement of arousal systems, suvorexant use causes a decrease in arousal and wakefulness, rather than having a direct sleep-promoting effect.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40216
Submission : 2024-08-02
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-27
Pay. Date : 2023-10-26
DMF Number : 38929
Submission : 2023-10-25
Status : Active
Type : II
NDC Package Code : 70966-0034
Start Marketing Date : 2014-08-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40216
Submission : 2024-08-02
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-27
Pay. Date : 2023-10-26
DMF Number : 38929
Submission : 2023-10-25
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territo...
About the Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, cat...
About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interventions keeping abrea...
About the Company : Saptagir Laboratories Private incorporated in 2016, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) and Intermediates for a wide range of therapeutic cat...
About the Company : In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (N...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
N-Boc-ethylenediamine
CAS Number : 57260-73-8
End Use API : Suvorexant
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid
CAS Number : 956317-36-5
End Use API : Suvorexant
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
2,5-dichloro-1,3 -benzoxazole
CAS Number : 3621-81-6
End Use API : Suvorexant
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
4-((2-aminoethyl)(5-chlorobenzo[d]oxazol-2-yl)amin...
CAS Number : 1276666-12-6
End Use API : Suvorexant
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
(R)-1-benzyl-5-methyl-1,4-diazepane
CAS Number : 1620097-06-4
End Use API : Suvorexant
About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...
Regulatory Info : RX
Registration Country : USA
Brand Name : BELSOMRA
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Packaging :
Approval Date : 2014-08-13
Application Number : 204569
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : BELSOMRA
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Packaging :
Approval Date : 2014-08-13
Application Number : 204569
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : BELSOMRA
Dosage Form : TABLET;ORAL
Dosage Strength : 15MG
Packaging :
Approval Date : 2014-08-13
Application Number : 204569
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : BELSOMRA
Dosage Form : TABLET;ORAL
Dosage Strength : 20MG
Packaging :
Approval Date : 2014-08-13
Application Number : 204569
Regulatory Info : RX
Registration Country : USA
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 328
2019 Revenue in Millions : 306
Growth (%) : 7
Main Therapeutic Indication : Sleep
Currency : USD
2021 Revenue in Millions : 318
2020 Revenue in Millions : 328
Growth (%) : -3
Main Therapeutic Indication : Sleep
Currency : USD
2022 Revenue in Millions : 258
2021 Revenue in Millions : 318
Growth (%) : -19
Main Therapeutic Indication : Sleep
Currency : USD
2023 Revenue in Millions : 231
2022 Revenue in Millions : 258
Growth (%) : -10
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 306
2018 Revenue in Millions : 260
Growth (%) : 18
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Suvorexant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Suvorexant, including repackagers and relabelers. The FDA regulates Suvorexant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Suvorexant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Suvorexant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Suvorexant supplier is an individual or a company that provides Suvorexant active pharmaceutical ingredient (API) or Suvorexant finished formulations upon request. The Suvorexant suppliers may include Suvorexant API manufacturers, exporters, distributors and traders.
click here to find a list of Suvorexant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Suvorexant DMF (Drug Master File) is a document detailing the whole manufacturing process of Suvorexant active pharmaceutical ingredient (API) in detail. Different forms of Suvorexant DMFs exist exist since differing nations have different regulations, such as Suvorexant USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Suvorexant DMF submitted to regulatory agencies in the US is known as a USDMF. Suvorexant USDMF includes data on Suvorexant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Suvorexant USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Suvorexant suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Suvorexant as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Suvorexant API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Suvorexant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Suvorexant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Suvorexant NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Suvorexant suppliers with NDC on PharmaCompass.
Suvorexant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Suvorexant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Suvorexant GMP manufacturer or Suvorexant GMP API supplier for your needs.
A Suvorexant CoA (Certificate of Analysis) is a formal document that attests to Suvorexant's compliance with Suvorexant specifications and serves as a tool for batch-level quality control.
Suvorexant CoA mostly includes findings from lab analyses of a specific batch. For each Suvorexant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Suvorexant may be tested according to a variety of international standards, such as European Pharmacopoeia (Suvorexant EP), Suvorexant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Suvorexant USP).
LOOKING FOR A SUPPLIER?